$TBPH Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Theravance Biopharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Theravance Biopharma, Inc.. Get notifications about new insider transactions in Theravance Biopharma, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 22 2019 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 27.00 | 5,798 | 156,546 | 183,446 | 189.2 K to 183.4 K (-3.06 %) |
Feb 22 2019 | TBPH | Theravance Biophar ... | SABESAN VIJAY | SVP, Technical Oper ... | Payment of Exercise | F | 27.00 | 4,568 | 123,336 | 149,672 | 154.2 K to 149.7 K (-2.96 %) |
Feb 22 2019 | TBPH | Theravance Biophar ... | PITZER KENNETH R | SVP, Prod Strat & C ... | Payment of Exercise | F | 27.00 | 3,674 | 99,198 | 266,650 | 270.3 K to 266.7 K (-1.36 %) |
Feb 22 2019 | TBPH | Theravance Biophar ... | PASQUALONE FRANK | SVP, Chief Comm Ops ... | Payment of Exercise | F | 27.00 | 4,919 | 132,813 | 323,671 | 328.6 K to 323.7 K (-1.50 %) |
Feb 22 2019 | TBPH | Theravance Biophar ... | HEGDE SHARATHCHANDRA S | SVP, Research | Payment of Exercise | F | 27.00 | 3,770 | 101,790 | 273,477 | 277.2 K to 273.5 K (-1.36 %) |
Feb 22 2019 | TBPH | Theravance Biophar ... | HAUMANN BRETT K | SVP Clin Dev & Chie ... | Payment of Exercise | F | 27.00 | 7,778 | 210,006 | 239,383 | 247.2 K to 239.4 K (-3.15 %) |
Feb 22 2019 | TBPH | Theravance Biophar ... | BRADY ANN | President, TBIL | Payment of Exercise | F | 27.00 | 3,023 | 81,621 | 74,330 | 77.4 K to 74.3 K (-3.91 %) |
Feb 07 2019 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Translational ... | Grant | A | 0.00 | 47,250 | 0 | 274,630 | 227.4 K to 274.6 K (+20.78 %) |
Feb 07 2019 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Translational ... | Grant | A | 0.00 | 65,000 | 0 | 227,380 | 162.4 K to 227.4 K (+40.03 %) |
Feb 07 2019 | TBPH | Theravance Biophar ... | Winningham Rick E | Chief Executive Off ... | Grant | A | 0.00 | 147,000 | 0 | 1,112,939 | 965.9 K to 1.1 M (+15.22 %) |
Feb 07 2019 | TBPH | Theravance Biophar ... | Winningham Rick E | Chief Executive Off ... | Grant | A | 0.00 | 170,000 | 0 | 965,939 | 795.9 K to 965.9 K (+21.36 %) |
Feb 07 2019 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 47,250 | 0 | 189,244 | 142 K to 189.2 K (+33.28 %) |
Feb 07 2019 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 65,000 | 0 | 141,994 | 77 K to 142 K (+84.42 %) |
Feb 07 2019 | TBPH | Theravance Biophar ... | PITZER KENNETH R | SVP, Prod Strat & C ... | Grant | A | 0.00 | 47,250 | 0 | 270,324 | 223.1 K to 270.3 K (+21.18 %) |
Feb 07 2019 | TBPH | Theravance Biophar ... | PITZER KENNETH R | SVP, Prod Strat & C ... | Grant | A | 0.00 | 65,000 | 0 | 223,074 | 158.1 K to 223.1 K (+41.12 %) |
Feb 07 2019 | TBPH | Theravance Biophar ... | PASQUALONE FRANK | SVP, Chief Comm Ops ... | Grant | A | 0.00 | 47,250 | 0 | 328,590 | 281.3 K to 328.6 K (+16.79 %) |
Feb 07 2019 | TBPH | Theravance Biophar ... | PASQUALONE FRANK | SVP, Chief Comm Ops ... | Grant | A | 0.00 | 65,000 | 0 | 281,340 | 216.3 K to 281.3 K (+30.05 %) |
Feb 07 2019 | TBPH | Theravance Biophar ... | HEGDE SHARATHCHANDRA S | SVP, Research | Grant | A | 0.00 | 47,250 | 0 | 277,247 | 230 K to 277.2 K (+20.54 %) |
Feb 07 2019 | TBPH | Theravance Biophar ... | HEGDE SHARATHCHANDRA S | SVP, Research | Grant | A | 0.00 | 65,000 | 0 | 229,997 | 165 K to 230 K (+39.39 %) |
Feb 07 2019 | TBPH | Theravance Biophar ... | HAUMANN BRETT K | SVP Clin Dev & Chie ... | Grant | A | 0.00 | 47,250 | 0 | 247,161 | 199.9 K to 247.2 K (+23.64 %) |
Feb 07 2019 | TBPH | Theravance Biophar ... | HAUMANN BRETT K | SVP Clin Dev & Chie ... | Grant | A | 0.00 | 65,000 | 0 | 199,911 | 134.9 K to 199.9 K (+48.18 %) |
Nov 21 2018 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Translational ... | Payment of Exercise | F | 24.79 | 4,373 | 108,407 | 162,380 | 166.8 K to 162.4 K (-2.62 %) |
Nov 21 2018 | TBPH | Theravance Biophar ... | Winningham Rick E | Chief Executive Off ... | Payment of Exercise | F | 24.79 | 15,557 | 385,658 | 795,939 | 811.5 K to 795.9 K (-1.92 %) |
Nov 21 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 24.79 | 7,006 | 173,679 | 76,994 | 84 K to 77 K (-8.34 %) |
Nov 21 2018 | TBPH | Theravance Biophar ... | PITZER KENNETH R | SVP, Prod Strat & C ... | Payment of Exercise | F | 24.79 | 3,908 | 96,879 | 158,074 | 162 K to 158.1 K (-2.41 %) |
Nov 21 2018 | TBPH | Theravance Biophar ... | PASQUALONE FRANK | SVP, Chief Comm Ops ... | Payment of Exercise | F | 24.79 | 5,735 | 142,171 | 216,340 | 222.1 K to 216.3 K (-2.58 %) |
Nov 21 2018 | TBPH | Theravance Biophar ... | HEGDE SHARATHCHANDRA S | SVP, Research | Payment of Exercise | F | 24.79 | 4,063 | 100,722 | 164,997 | 169.1 K to 165 K (-2.40 %) |
Nov 21 2018 | TBPH | Theravance Biophar ... | HAUMANN BRETT K | SVP Clin Dev & Chie ... | Payment of Exercise | F | 24.79 | 7,368 | 182,653 | 134,911 | 142.3 K to 134.9 K (-5.18 %) |
Nov 21 2018 | TBPH | Theravance Biophar ... | GALA RENEE D | SVP, Chief Financia ... | Payment of Exercise | F | 24.79 | 6,697 | 166,019 | 157,657 | 164.4 K to 157.7 K (-4.07 %) |
Sep 14 2018 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Translational ... | Sell | S | 28.50 | 6,393 | 182,201 | 166,753 | 173.1 K to 166.8 K (-3.69 %) |
Aug 29 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 27.71 | 7,119 | 197,282 | 84,000 | 91.1 K to 84 K (-7.81 %) |
Aug 22 2018 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Translational ... | Payment of Exercise | F | 26.95 | 5,508 | 148,441 | 173,146 | 178.7 K to 173.1 K (-3.08 %) |
Aug 22 2018 | TBPH | Theravance Biophar ... | Winningham Rick E | Chief Executive Off ... | Payment of Exercise | F | 26.95 | 15,557 | 419,261 | 904,063 | 919.6 K to 904.1 K (-1.69 %) |
Aug 22 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 26.95 | 7,005 | 188,785 | 91,119 | 98.1 K to 91.1 K (-7.14 %) |
Aug 22 2018 | TBPH | Theravance Biophar ... | PITZER KENNETH R | SVP, Prod Strat & C ... | Payment of Exercise | F | 26.95 | 5,043 | 135,909 | 161,982 | 167 K to 162 K (-3.02 %) |
Aug 22 2018 | TBPH | Theravance Biophar ... | PASQUALONE FRANK | SVP, Chief Comm Ops ... | Payment of Exercise | F | 26.95 | 5,735 | 154,558 | 222,075 | 227.8 K to 222.1 K (-2.52 %) |
Aug 22 2018 | TBPH | Theravance Biophar ... | HEGDE SHARATHCHANDRA S | SVP, Research | Payment of Exercise | F | 26.95 | 5,198 | 140,086 | 169,060 | 174.3 K to 169.1 K (-2.98 %) |
Aug 22 2018 | TBPH | Theravance Biophar ... | HAUMANN BRETT K | SVP Clin Dev & Chie ... | Payment of Exercise | F | 26.95 | 6,683 | 180,107 | 142,279 | 149 K to 142.3 K (-4.49 %) |
Aug 22 2018 | TBPH | Theravance Biophar ... | GALA RENEE D | SVP, Chief Financia ... | Payment of Exercise | F | 26.95 | 6,695 | 180,430 | 164,354 | 171 K to 164.4 K (-3.91 %) |
Aug 16 2018 | TBPH | Theravance Biophar ... | GALA RENEE D | SVP, Chief Financia ... | Sell | S | 27.43 | 1,700 | 46,623 | 171,049 | 172.7 K to 171 K (-0.98 %) |
Aug 16 2018 | TBPH | Theravance Biophar ... | GALA RENEE D | SVP, Chief Financia ... | Sell | S | 26.71 | 39,839 | 1,064,032 | 172,749 | 212.6 K to 172.7 K (-18.74 %) |
Aug 16 2018 | TBPH | Theravance Biophar ... | GALA RENEE D | SVP, Chief Financia ... | Sell | S | 27.74 | 2,204 | 61,136 | 212,588 | 214.8 K to 212.6 K (-1.03 %) |
Aug 09 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 27.85 | 25,355 | 706,182 | 98,124 | 123.5 K to 98.1 K (-20.53 %) |
Aug 09 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 28.03 | 4,127 | 115,686 | 123,479 | 127.6 K to 123.5 K (-3.23 %) |
Aug 09 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 28.99 | 1,818 | 52,707 | 127,606 | 129.4 K to 127.6 K (-1.40 %) |
Jun 08 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 23.66 | 3,900 | 92,260 | 129,424 | 133.3 K to 129.4 K (-2.93 %) |
Jun 08 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 24.09 | 10,140 | 244,268 | 133,324 | 143.5 K to 133.3 K (-7.07 %) |
May 23 2018 | TBPH | Theravance Biophar ... | MALKIEL BURTON G | Director | Buy | P | 22.54 | 1,000 | 22,540 | 56,757 | 55.8 K to 56.8 K (+1.79 %) |
May 22 2018 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Translational ... | Payment of Exercise | F | 24.31 | 19,524 | 474,628 | 178,654 | 198.2 K to 178.7 K (-9.85 %) |
May 22 2018 | TBPH | Theravance Biophar ... | Winningham Rick E | Chief Executive Off ... | Payment of Exercise | F | 24.31 | 67,617 | 1,643,769 | 919,620 | 987.2 K to 919.6 K (-6.85 %) |
May 22 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 24.31 | 21,812 | 530,250 | 143,464 | 165.3 K to 143.5 K (-13.20 %) |
May 22 2018 | TBPH | Theravance Biophar ... | PITZER KENNETH R | SVP, Prod Strat & C ... | Payment of Exercise | F | 24.31 | 18,779 | 456,517 | 167,025 | 185.8 K to 167 K (-10.11 %) |
May 22 2018 | TBPH | Theravance Biophar ... | PASQUALONE FRANK | SVP, Chief Comm Ops ... | Payment of Exercise | F | 24.31 | 18,424 | 447,887 | 227,810 | 246.2 K to 227.8 K (-7.48 %) |
May 22 2018 | TBPH | Theravance Biophar ... | HEGDE SHARATHCHANDRA S | SVP, Research | Payment of Exercise | F | 24.31 | 19,103 | 464,394 | 174,258 | 193.4 K to 174.3 K (-9.88 %) |
May 22 2018 | TBPH | Theravance Biophar ... | HAUMANN BRETT K | SVP Clin Dev & Chie ... | Payment of Exercise | F | 24.31 | 26,991 | 656,151 | 148,962 | 176 K to 149 K (-15.34 %) |
May 22 2018 | TBPH | Theravance Biophar ... | GALA RENEE D | SVP, Chief Financia ... | Payment of Exercise | F | 24.31 | 21,230 | 516,101 | 214,792 | 236 K to 214.8 K (-8.99 %) |
May 22 2018 | TBPH | Theravance Biophar ... | GALA RENEE D | SVP, Chief Financia ... | Sell | S | 24.29 | 10,000 | 242,877 | 236,022 | 246 K to 236 K (-4.06 %) |
May 16 2018 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Translational ... | Grant | A | 0.00 | 33,750 | 0 | 198,178 | 164.4 K to 198.2 K (+20.53 %) |
May 16 2018 | TBPH | Theravance Biophar ... | Winningham Rick E | Chief Executive Off ... | Grant | A | 0.00 | 105,000 | 0 | 987,237 | 882.2 K to 987.2 K (+11.90 %) |
May 16 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 33,750 | 0 | 165,276 | 131.5 K to 165.3 K (+25.66 %) |
May 16 2018 | TBPH | Theravance Biophar ... | PITZER KENNETH R | SVP, Prod Strat & C ... | Grant | A | 0.00 | 33,750 | 0 | 185,804 | 152.1 K to 185.8 K (+22.20 %) |
May 16 2018 | TBPH | Theravance Biophar ... | PASQUALONE FRANK | SVP, Chief Comm Ops ... | Grant | A | 0.00 | 33,750 | 0 | 246,234 | 212.5 K to 246.2 K (+15.88 %) |
May 16 2018 | TBPH | Theravance Biophar ... | HEGDE SHARATHCHANDRA S | SVP, Research | Grant | A | 0.00 | 33,750 | 0 | 193,361 | 159.6 K to 193.4 K (+21.15 %) |
May 16 2018 | TBPH | Theravance Biophar ... | HAUMANN BRETT K | SVP Clin Dev & Chie ... | Grant | A | 0.00 | 33,750 | 0 | 175,953 | 142.2 K to 176 K (+23.73 %) |
May 16 2018 | TBPH | Theravance Biophar ... | GALA RENEE D | SVP, Chief Financia ... | Grant | A | 0.00 | 33,750 | 0 | 246,022 | 212.3 K to 246 K (+15.90 %) |
May 03 2018 | TBPH | Theravance Biophar ... | YOUNG WILLIAM D | Director | Option Exercise | A | 24.43 | 6,000 | 146,580 | 6,000 | |
May 03 2018 | TBPH | Theravance Biophar ... | YOUNG WILLIAM D | Director | Grant | A | 0.00 | 8,186 | 0 | 43,310 | 35.1 K to 43.3 K (+23.31 %) |
May 03 2018 | TBPH | Theravance Biophar ... | WHITESIDES GEORGE M | Director | Option Exercise | A | 24.43 | 6,000 | 146,580 | 6,000 | |
May 03 2018 | TBPH | Theravance Biophar ... | WHITESIDES GEORGE M | Director | Grant | A | 0.00 | 8,186 | 0 | 192,578 | 184.4 K to 192.6 K (+4.44 %) |
May 03 2018 | TBPH | Theravance Biophar ... | Smaldone Alsup Laurie | Director | Option Exercise | A | 24.43 | 6,000 | 146,580 | 6,000 | |
May 03 2018 | TBPH | Theravance Biophar ... | Smaldone Alsup Laurie | Director | Grant | A | 0.00 | 8,186 | 0 | 9,962 | 1.8 K to 10 K (+460.92 %) |
May 03 2018 | TBPH | Theravance Biophar ... | RINGROSE PETER S | Director | Option Exercise | A | 24.43 | 6,000 | 146,580 | 6,000 | |
May 03 2018 | TBPH | Theravance Biophar ... | RINGROSE PETER S | Director | Grant | A | 0.00 | 8,186 | 0 | 29,614 | 21.4 K to 29.6 K (+38.20 %) |
May 03 2018 | TBPH | Theravance Biophar ... | O'Connor Donal | Director | Option Exercise | A | 24.43 | 6,000 | 146,580 | 6,000 | |
May 03 2018 | TBPH | Theravance Biophar ... | O'Connor Donal | Director | Grant | A | 0.00 | 8,186 | 0 | 23,186 | 15 K to 23.2 K (+54.57 %) |
May 03 2018 | TBPH | Theravance Biophar ... | Molineaux Susan | Director | Option Exercise | A | 24.43 | 6,000 | 146,580 | 6,000 | |
May 03 2018 | TBPH | Theravance Biophar ... | Molineaux Susan | Director | Grant | A | 0.00 | 8,186 | 0 | 14,186 | 6 K to 14.2 K (+136.43 %) |
May 03 2018 | TBPH | Theravance Biophar ... | MITCHELL DEAN J | Director | Option Exercise | A | 24.43 | 6,000 | 146,580 | 6,000 | |
May 03 2018 | TBPH | Theravance Biophar ... | MITCHELL DEAN J | Director | Grant | A | 0.00 | 8,186 | 0 | 26,186 | 18 K to 26.2 K (+45.48 %) |
May 03 2018 | TBPH | Theravance Biophar ... | MALKIEL BURTON G | Director | Option Exercise | A | 24.43 | 6,000 | 146,580 | 6,000 | |
May 03 2018 | TBPH | Theravance Biophar ... | MALKIEL BURTON G | Director | Grant | A | 0.00 | 8,186 | 0 | 55,757 | 47.6 K to 55.8 K (+17.21 %) |
May 03 2018 | TBPH | Theravance Biophar ... | Gunderson Robert V JR | Director | Option Exercise | A | 24.43 | 6,000 | 146,580 | 6,000 | |
May 03 2018 | TBPH | Theravance Biophar ... | Gunderson Robert V JR | Director | Grant | A | 0.00 | 8,186 | 0 | 43,245 | 35.1 K to 43.2 K (+23.35 %) |
May 03 2018 | TBPH | Theravance Biophar ... | BROSHY ERAN | Director | Option Exercise | A | 24.43 | 6,000 | 146,580 | 6,000 | |
May 03 2018 | TBPH | Theravance Biophar ... | BROSHY ERAN | Director | Grant | A | 0.00 | 8,186 | 0 | 26,186 | 18 K to 26.2 K (+45.48 %) |
Feb 22 2018 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Translational ... | Payment of Exercise | F | 29.09 | 4,566 | 132,825 | 163,563 | 168.1 K to 163.6 K (-2.72 %) |
Feb 22 2018 | TBPH | Theravance Biophar ... | Winningham Rick E | Chief Executive Off ... | Payment of Exercise | F | 29.09 | 13,005 | 378,315 | 881,372 | 894.4 K to 881.4 K (-1.45 %) |
Feb 22 2018 | TBPH | Theravance Biophar ... | SULIMAN SHEHNAAZ | SVP, Corp Dev & Str ... | Payment of Exercise | F | 29.09 | 8,770 | 255,119 | 101,230 | 110 K to 101.2 K (-7.97 %) |
Feb 22 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 29.09 | 5,587 | 162,526 | 130,661 | 136.2 K to 130.7 K (-4.10 %) |
Feb 22 2018 | TBPH | Theravance Biophar ... | PITZER KENNETH R | SVP, Prod Strat & C ... | Payment of Exercise | F | 29.09 | 4,252 | 123,691 | 152,054 | 156.3 K to 152.1 K (-2.72 %) |
Feb 22 2018 | TBPH | Theravance Biophar ... | PASQUALONE FRANK | SVP, Chief Comm Ops ... | Payment of Exercise | F | 29.09 | 4,741 | 137,916 | 211,619 | 216.4 K to 211.6 K (-2.19 %) |
Feb 22 2018 | TBPH | Theravance Biophar ... | HEGDE SHARATHCHANDRA S | SVP, Research | Payment of Exercise | F | 29.09 | 4,349 | 126,512 | 159,611 | 164 K to 159.6 K (-2.65 %) |
Feb 22 2018 | TBPH | Theravance Biophar ... | HAUMANN BRETT K | SVP Clin Dev & Chie ... | Payment of Exercise | F | 29.09 | 8,293 | 241,243 | 142,203 | 150.5 K to 142.2 K (-5.51 %) |
Feb 22 2018 | TBPH | Theravance Biophar ... | GALA RENEE D | SVP, Chief Financia ... | Payment of Exercise | F | 29.09 | 5,387 | 156,708 | 211,407 | 216.8 K to 211.4 K (-2.48 %) |
Feb 15 2018 | TBPH | Theravance Biophar ... | Smaldone Alsup Laurie | Director | Option Exercise | A | 28.14 | 1,500 | 42,210 | 1,500 | |
Feb 15 2018 | TBPH | Theravance Biophar ... | Smaldone Alsup Laurie | Director | Option Exercise | A | 28.14 | 12,000 | 337,680 | 12,000 | |
Feb 15 2018 | TBPH | Theravance Biophar ... | Smaldone Alsup Laurie | Director | Grant | A | 0.00 | 1,776 | 0 | 1,776 | 0 to 1.8 K |
Feb 14 2018 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Translational ... | Grant | A | 0.00 | 9,000 | 0 | 168,129 | 159.1 K to 168.1 K (+5.66 %) |
Feb 14 2018 | TBPH | Theravance Biophar ... | Winningham Rick E | Chief Executive Off ... | Grant | A | 0.00 | 28,000 | 0 | 894,377 | 866.4 K to 894.4 K (+3.23 %) |
Feb 14 2018 | TBPH | Theravance Biophar ... | SULIMAN SHEHNAAZ | SVP, Corp Dev & Str ... | Grant | A | 0.00 | 25,000 | 0 | 110,000 | 85 K to 110 K (+29.41 %) |
Feb 14 2018 | TBPH | Theravance Biophar ... | SULIMAN SHEHNAAZ | SVP, Corp Dev & Str ... | Grant | A | 0.00 | 65,000 | 0 | 85,000 | 20 K to 85 K (+325.00 %) |
Feb 14 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 9,000 | 0 | 136,248 | 127.2 K to 136.2 K (+7.07 %) |
Feb 14 2018 | TBPH | Theravance Biophar ... | PITZER KENNETH R | SVP, Prod Strat & C ... | Grant | A | 0.00 | 9,000 | 0 | 156,306 | 147.3 K to 156.3 K (+6.11 %) |
Nov 22 2017 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Translational ... | Payment of Exercise | F | 28.58 | 5,503 | 157,276 | 159,129 | 164.6 K to 159.1 K (-3.34 %) |
Nov 22 2017 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 28.58 | 7,079 | 202,318 | 127,248 | 134.3 K to 127.2 K (-5.27 %) |
Nov 22 2017 | TBPH | Theravance Biophar ... | PITZER KENNETH R | SVP, Prod Strat & C ... | Payment of Exercise | F | 28.58 | 5,014 | 143,300 | 147,306 | 152.3 K to 147.3 K (-3.29 %) |
Nov 22 2017 | TBPH | Theravance Biophar ... | PASQUALONE FRANK | SVP, Chief Comm Ops ... | Payment of Exercise | F | 28.58 | 5,820 | 166,336 | 207,360 | 213.2 K to 207.4 K (-2.73 %) |
Nov 22 2017 | TBPH | Theravance Biophar ... | HEGDE SHARATHCHANDRA S | SVP, Research | Payment of Exercise | F | 28.58 | 5,177 | 147,959 | 154,960 | 160.1 K to 155 K (-3.23 %) |
Nov 22 2017 | TBPH | Theravance Biophar ... | HAUMANN BRETT K | SVP Clin Dev & Chie ... | Payment of Exercise | F | 28.58 | 7,846 | 224,239 | 141,496 | 149.3 K to 141.5 K (-5.25 %) |
Nov 22 2017 | TBPH | Theravance Biophar ... | GALA RENEE D | SVP, Chief Financia ... | Payment of Exercise | F | 28.58 | 6,753 | 193,001 | 207,794 | 214.5 K to 207.8 K (-3.15 %) |
Sep 08 2017 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 30.77 | 14,670 | 451,350 | 134,327 | 149 K to 134.3 K (-9.85 %) |
Aug 23 2017 | TBPH | Theravance Biophar ... | PASQUALONE FRANK | SVP, Chief Comm Ops ... | Buy | P | 26.34 | 4,000 | 105,359 | 213,180 | 209.2 K to 213.2 K (+1.91 %) |
Aug 22 2017 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Translational ... | Payment of Exercise | F | 27.40 | 5,502 | 150,755 | 164,632 | 170.1 K to 164.6 K (-3.23 %) |
Aug 22 2017 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 27.40 | 7,079 | 193,965 | 148,997 | 156.1 K to 149 K (-4.54 %) |
Aug 22 2017 | TBPH | Theravance Biophar ... | PITZER KENNETH R | SVP, Prod Strat & C ... | Payment of Exercise | F | 27.40 | 5,013 | 137,356 | 152,320 | 157.3 K to 152.3 K (-3.19 %) |
Aug 22 2017 | TBPH | Theravance Biophar ... | PASQUALONE FRANK | SVP, Chief Comm Ops ... | Payment of Exercise | F | 27.40 | 5,820 | 159,468 | 209,180 | 215 K to 209.2 K (-2.71 %) |
Aug 22 2017 | TBPH | Theravance Biophar ... | HEGDE SHARATHCHANDRA S | SVP, Research | Payment of Exercise | F | 27.40 | 5,176 | 141,822 | 160,137 | 165.3 K to 160.1 K (-3.13 %) |
Aug 22 2017 | TBPH | Theravance Biophar ... | HAUMANN BRETT K | SVP Clin Dev & Chie ... | Payment of Exercise | F | 27.40 | 7,064 | 193,554 | 149,342 | 156.4 K to 149.3 K (-4.52 %) |
Aug 22 2017 | TBPH | Theravance Biophar ... | GALA RENEE D | SVP, Chief Financia ... | Payment of Exercise | F | 27.40 | 6,752 | 185,005 | 214,547 | 221.3 K to 214.5 K (-3.05 %) |
Aug 14 2017 | TBPH | Theravance Biophar ... | WHITESIDES GEORGE M | Director | Buy | P | 24.69 | 4,000 | 98,764 | 4,000 | 0 to 4 K |
Aug 14 2017 | TBPH | Theravance Biophar ... | MALKIEL BURTON G | Director | Buy | P | 24.59 | 15,000 | 368,816 | 15,000 | 0 to 15 K |
Aug 14 2017 | TBPH | Theravance Biophar ... | MALKIEL BURTON G | Director | Buy | P | 24.59 | 15,000 | 368,855 | 47,571 | 32.6 K to 47.6 K (+46.05 %) |
Aug 11 2017 | TBPH | Theravance Biophar ... | Fore Henrietta | Director | Buy | P | 23.99 | 6,000 | 143,932 | 24,000 | 18 K to 24 K (+33.33 %) |
Aug 11 2017 | TBPH | Theravance Biophar ... | Winningham Rick E | Chief Executive Off ... | Buy | P | 24.50 | 10,000 | 245,000 | 866,377 | 856.4 K to 866.4 K (+1.17 %) |
Aug 03 2017 | TBPH | Theravance Biophar ... | SULIMAN SHEHNAAZ | SVP, Corp Dev & Str ... | Option Exercise | A | 31.93 | 170,000 | 5,428,100 | 170,000 | |
Aug 03 2017 | TBPH | Theravance Biophar ... | SULIMAN SHEHNAAZ | SVP, Corp Dev & Str ... | Grant | A | 0.00 | 20,000 | 0 | 20,000 | 0 to 20 K |
May 23 2017 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Translational ... | Payment of Exercise | F | 36.83 | 5,503 | 202,675 | 170,134 | 175.6 K to 170.1 K (-3.13 %) |
May 23 2017 | TBPH | Theravance Biophar ... | Winningham Rick E | Chief Executive Off ... | Payment of Exercise | F | 36.83 | 15,460 | 569,392 | 856,377 | 871.8 K to 856.4 K (-1.77 %) |
May 23 2017 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 36.83 | 7,079 | 260,720 | 156,076 | 163.2 K to 156.1 K (-4.34 %) |
May 23 2017 | TBPH | Theravance Biophar ... | PITZER KENNETH R | SVP, Prod Strat & C ... | Payment of Exercise | F | 36.83 | 5,014 | 184,666 | 157,333 | 162.3 K to 157.3 K (-3.09 %) |
May 23 2017 | TBPH | Theravance Biophar ... | PASQUALONE FRANK | SVP, Chief Comm Ops ... | Payment of Exercise | F | 36.83 | 5,820 | 214,351 | 215,000 | 220.8 K to 215 K (-2.64 %) |
May 23 2017 | TBPH | Theravance Biophar ... | HEGDE SHARATHCHANDRA S | SVP, Research | Payment of Exercise | F | 36.83 | 5,177 | 190,669 | 165,313 | 170.5 K to 165.3 K (-3.04 %) |
May 23 2017 | TBPH | Theravance Biophar ... | HAUMANN BRETT K | SVP Clin Dev & Chie ... | Payment of Exercise | F | 36.83 | 7,065 | 260,204 | 156,406 | 163.5 K to 156.4 K (-4.32 %) |
May 23 2017 | TBPH | Theravance Biophar ... | GALA RENEE D | SVP, Chief Financia ... | Payment of Exercise | F | 36.83 | 6,753 | 248,713 | 221,299 | 228.1 K to 221.3 K (-2.96 %) |
May 18 2017 | TBPH | Theravance Biophar ... | YOUNG WILLIAM D | Director | Grant | A | 0.00 | 6,000 | 0 | 35,124 | 29.1 K to 35.1 K (+20.60 %) |
May 18 2017 | TBPH | Theravance Biophar ... | WHITESIDES GEORGE M | Director | Grant | A | 0.00 | 6,000 | 0 | 184,392 | 178.4 K to 184.4 K (+3.36 %) |
May 18 2017 | TBPH | Theravance Biophar ... | RINGROSE PETER S | Director | Grant | A | 0.00 | 6,000 | 0 | 21,428 | 15.4 K to 21.4 K (+38.89 %) |
May 18 2017 | TBPH | Theravance Biophar ... | O'Connor Donal | Director | Grant | A | 0.00 | 6,000 | 0 | 15,000 | 9 K to 15 K (+66.67 %) |
May 18 2017 | TBPH | Theravance Biophar ... | Molineaux Susan | Director | Grant | A | 0.00 | 6,000 | 0 | 12,000 | 6 K to 12 K (+100.00 %) |
May 18 2017 | TBPH | Theravance Biophar ... | MITCHELL DEAN J | Director | Grant | A | 0.00 | 6,000 | 0 | 18,000 | 12 K to 18 K (+50.00 %) |
May 18 2017 | TBPH | Theravance Biophar ... | MALKIEL BURTON G | Director | Grant | A | 0.00 | 6,000 | 0 | 32,571 | 26.6 K to 32.6 K (+22.58 %) |
May 18 2017 | TBPH | Theravance Biophar ... | Gunderson Robert V JR | Director | Grant | A | 0.00 | 6,000 | 0 | 35,059 | 29.1 K to 35.1 K (+20.65 %) |
May 18 2017 | TBPH | Theravance Biophar ... | Fore Henrietta | Director | Grant | A | 0.00 | 6,000 | 0 | 18,000 | 12 K to 18 K (+50.00 %) |
May 18 2017 | TBPH | Theravance Biophar ... | BROSHY ERAN | Director | Grant | A | 0.00 | 6,000 | 0 | 18,000 | 12 K to 18 K (+50.00 %) |
Mar 08 2017 | TBPH | Theravance Biophar ... | HAUMANN BRETT K | SVP Clin Dev & Chie ... | Sell | S | 30.80 | 424 | 13,059 | 163,471 | 163.9 K to 163.5 K (-0.26 %) |
Mar 08 2017 | TBPH | Theravance Biophar ... | HAUMANN BRETT K | SVP Clin Dev & Chie ... | Sell | S | 31.52 | 13,576 | 427,916 | 163,895 | 177.5 K to 163.9 K (-7.65 %) |
Mar 07 2017 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 31.86 | 26,829 | 854,772 | 161,453 | 188.3 K to 161.5 K (-14.25 %) |
Feb 22 2017 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Translational ... | Payment of Exercise | F | 33.78 | 10,397 | 351,211 | 173,935 | 184.3 K to 173.9 K (-5.64 %) |
Feb 22 2017 | TBPH | Theravance Biophar ... | Winningham Rick E | Chief Executive Off ... | Payment of Exercise | F | 33.78 | 33,264 | 1,123,658 | 870,135 | 903.4 K to 870.1 K (-3.68 %) |
Feb 22 2017 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 33.78 | 12,440 | 420,223 | 188,282 | 200.7 K to 188.3 K (-6.20 %) |